Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 8,481,093 shares, a decline of 5.8% from the February 28th total of 9,005,539 shares. Currently, 5.6% of the company’s shares are sold short. Based on an average trading volume of 435,889 shares, the days-to-cover ratio is currently 19.5 days.

NYSEAMERICAN:NAVB opened at $0.14 on Thursday. Navidea Biopharmaceuticals has a 52 week low of $0.10 and a 52 week high of $0.40.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last posted its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The company had revenue of $0.12 million for the quarter.

In other Navidea Biopharmaceuticals news, major shareholder John K. Jr. Scott acquired 357,143 shares of the stock in a transaction dated Friday, March 22nd. The stock was purchased at an average cost of $0.14 per share, for a total transaction of $50,000.02. Following the acquisition, the insider now owns 22,261,565 shares in the company, valued at approximately $3,116,619.10. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/navidea-biopharmaceuticals-inc-navb-short-interest-down-5-8-in-march/2922577.html.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

See Also: Why do companies engage in swaps?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.